Bauer, T., Cho, B. C., Heist, R., Bazhenova, L., Werner, T., Goel, S., Kim, D.-W., Adkins, D., Carvajal, R. D., Alva, A., Eaton, K., Wang, J., Liu, Y., Yan, X., Christensen, J., Neuteboom, S., Chao, R., & Pant, S. (2022). First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Investigational New Drugs, 40(5), 990–1000. https://doi.org/10.1007/s10637-022-01274-y

Falchook, G. S., Peeters, M., Rottey, S., Dirix, L. Y., Obermannova, R., Cohen, J. E., Perets, R., Frommer, R. S., Bauer, T. M., Wang, J. S., Carvajal, R. D., Sabari, J., Chapman, S., Zhang, W., Calderon, B., & Peterson, D. A. (2021). A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. Investigational New Drugs, 39(5), 1284–1297. https://doi.org/10.1007/s10637-021-01088-4

Dowlati, A., Harvey, R. D., Carvajal, R. D., Hamid, O., Klempner, S. J., Kauh, J. S. W., Peterson, D. A., Yu, D., Chapman, S. C., Szpurka, A. M., Carlsen, M., Quinlan, T., & Wesolowski, R. (2021). LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. Investigational New Drugs, 39(4), 1057–1071. https://doi.org/10.1007/s10637-021-01084-8